| Literature DB >> 20816751 |
Satoshi Nishiyama1, Hiroshi Shitara, Kazuto Nakada, Tomio Ono, Akitsugu Sato, Hidenori Suzuki, Tetsuhiro Ogawa, Haruhiko Masaki, Jun-Ichi Hayashi, Hiromichi Yonekawa.
Abstract
The phenotypes of mitochondrial diseases caused by mutations in mitochondrial DNA (mtDNA) have been proposed to be strictly regulated by the proportion of wild-type and pathogenically mutated mtDNAs. More specifically, it is thought that the onset of the disease phenotype occurs when cells cannot maintain the proper mitochondrial function because of an over-abundance of pathological mtDNA. Therapies that cause a decrease in the pathogenic mtDNA population have been proposed as a treatment for mitochondrial diseases, but these therapies are difficult to apply in practice. In this report, we present a novel concept: to improve mitochondrial disease phenotypes via an increase in the absolute copy number of the wild-type mtDNA population in pathogenic cells even when the relative proportion of mtDNA genotypes remains unchanged. We have succeeded in ameliorating the typical symptoms of mitochondrial disease in a model mouse line by the over-expression of the mitochondrial transcription factor A (Tfam) followed by an increase of the mtDNA copy number. This new concept should lead to the development of a novel therapeutic treatment for mitochondrial diseases.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20816751 DOI: 10.1016/j.bbrc.2010.08.143
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575